Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of ZYME is 27 and suggests 14% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
Buy
Sell